ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $2,471,422 | -49.7% | 115,487 | -5.0% | 0.00% | -50.0% |
Q1 2023 | $4,917,625 | -13.6% | 121,603 | -0.6% | 0.00% | 0.0% |
Q4 2022 | $5,693,954 | -13.9% | 122,398 | -4.0% | 0.00% | -20.0% |
Q3 2022 | $6,614,000 | +7.6% | 127,515 | -1.9% | 0.01% | 0.0% |
Q2 2022 | $6,146,000 | -29.7% | 130,011 | +5.9% | 0.01% | -16.7% |
Q1 2022 | $8,739,000 | -4.4% | 122,768 | +0.4% | 0.01% | +20.0% |
Q4 2021 | $9,143,000 | +27.1% | 122,261 | -3.5% | 0.01% | 0.0% |
Q3 2021 | $7,196,000 | +26.8% | 126,670 | -1.8% | 0.01% | +25.0% |
Q2 2021 | $5,676,000 | -10.0% | 128,962 | +0.9% | 0.00% | 0.0% |
Q1 2021 | $6,306,000 | +17.9% | 127,853 | +0.6% | 0.00% | 0.0% |
Q4 2020 | $5,350,000 | -11.3% | 127,080 | -3.6% | 0.00% | -20.0% |
Q3 2020 | $6,033,000 | -4.1% | 131,793 | +5.2% | 0.01% | -16.7% |
Q2 2020 | $6,288,000 | -1.6% | 125,233 | +0.8% | 0.01% | -14.3% |
Q1 2020 | $6,390,000 | -19.9% | 124,253 | -3.8% | 0.01% | 0.0% |
Q4 2019 | $7,976,000 | +5.6% | 129,108 | +2.7% | 0.01% | 0.0% |
Q3 2019 | $7,555,000 | -29.9% | 125,744 | -1.6% | 0.01% | -30.0% |
Q2 2019 | $10,782,000 | -18.3% | 127,782 | -7.5% | 0.01% | -16.7% |
Q1 2019 | $13,201,000 | +35.9% | 138,207 | +0.8% | 0.01% | +20.0% |
Q4 2018 | $9,716,000 | -18.5% | 137,169 | -1.7% | 0.01% | -9.1% |
Q3 2018 | $11,923,000 | -17.3% | 139,524 | +12.1% | 0.01% | -15.4% |
Q2 2018 | $14,419,000 | +57.0% | 124,412 | +9.6% | 0.01% | +44.4% |
Q1 2018 | $9,185,000 | +42.4% | 113,524 | +3.2% | 0.01% | +50.0% |
Q4 2017 | $6,452,000 | +27.4% | 109,959 | +1.6% | 0.01% | +20.0% |
Q3 2017 | $5,065,000 | +32.5% | 108,224 | +1.9% | 0.01% | +25.0% |
Q2 2017 | $3,823,000 | +16.8% | 106,253 | +0.0% | 0.00% | 0.0% |
Q1 2017 | $3,272,000 | -4.7% | 106,238 | +3.6% | 0.00% | 0.0% |
Q4 2016 | $3,435,000 | +27.6% | 102,525 | +1.3% | 0.00% | 0.0% |
Q3 2016 | $2,692,000 | +30.6% | 101,178 | +8.2% | 0.00% | +33.3% |
Q2 2016 | $2,061,000 | -22.8% | 93,477 | +2.9% | 0.00% | -25.0% |
Q1 2016 | $2,668,000 | -6.4% | 90,825 | +5.2% | 0.00% | 0.0% |
Q4 2015 | $2,850,000 | -4.4% | 86,321 | +4.6% | 0.00% | -20.0% |
Q3 2015 | $2,982,000 | – | 82,526 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |